Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THIO and Cemiplimab in 3L NSCLC
NCT06908304Phase 3Recruiting
- Sponsor
- MAIA Biotechnology, Inc.
- Start
- Dec 2025
- Primary completion
- Jul 2027
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 4
01
Overview
A Phase 3 trial of ateganosine in non-small cell lung cancer (NSCLC), sponsored by MAIA Biotechnology, Inc.. Started Dec 2025; status: recruiting.
02
Drugs
ateganosine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06908304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908304.